Literature DB >> 3949965

Serum cytotoxicity to oligodendrocytes in multiple sclerosis and controls: assessment by 51Cr release assay.

A Suzumura, R P Lisak, D H Silberberg.   

Abstract

In order to quantitate oligodendrocyte cytotoxicity induced by sera from patients with multiple sclerosis (MS) and control sera, we established a 51Cr release assay system using cultured oligodendrocytes as target cells. With this assay system, we detected serum-induced cytotoxicity in isolated oligodendrocytes in sera from patients with MS, other neurological diseases (OND) and normal individuals. Oligodendrocytes were much more susceptible than astrocytes. The serum cytotoxicity was abolished by heating sera at either 56 degrees C or 50 degrees C for 30 min, and disappeared in storage at 23 degrees C for 1 month or at 4 degrees C for 2 months. Addition of fresh guinea pig serum as a source of complement did not restore the cytotoxic effect. Although the serum factor cytotoxic to oligodendrocytes is not specific for sera from patients with MS, it is possible that it may damage oligodendrocytes if the blood-brain barrier is impaired, as occurs in MS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3949965     DOI: 10.1016/0165-5728(86)90115-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Characteristics of in vitro cytotoxic effects of myelin basic protein-reactive T cell lines on syngeneic oligodendrocytes.

Authors:  K Kawai; B Zweiman
Journal:  J Neuroimmunol       Date:  1990-01       Impact factor: 3.478

2.  MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon.

Authors:  A Suzumura; S G Mezitis; N K Gonatas; D H Silberberg
Journal:  J Neuroimmunol       Date:  1987 Jul-Aug       Impact factor: 3.478

3.  Human oligodendrocytes are susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes.

Authors:  T C Ruijs; M S Freedman; Y G Grenier; A Olivier; J P Antel
Journal:  J Neuroimmunol       Date:  1990-05       Impact factor: 3.478

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.